UPCOMING EVENT
Cell & Gene Meeting on the Mesa
Location: 2400 E Missouri Ave, Phoenix, AZ 85016
Oct. 06, 2025
FIND OUT MORE
Location: 2400 E Missouri Ave, Phoenix, AZ 85016
Oct. 06, 2025
FIND OUT MOREDive into our latest snapshot of the cell and gene therapy sector, with an update on the 2025 clinical milestones, commercial trends, and regulatory developments. Our latest snapshot also provides an overview of the clinical pipeline for cell and gene therapy products for the remainder of the year.
View our latest data highlighting trends for clinical trials, total developers, and investment in the cell and gene therapy sector. ARM's data features a new methodology that provides an even more accurate pulse on sector activity.
ARM commends the U.S. Food and Drug Administration for its decision to eliminate the Risk Evaluation and Mitigation Strategies (REMS) program and reduce other labeling restrictions for autologous CAR-T cell therapies. This evidence-based decision significantly lowers barriers for physicians administering and patients seeking these transformative treatments.
In June 2025, ARM and CEOs from 30 + cell and gene therapy companies issued a joint call to EU leaders urging them that Europe must seize this once-in-a-generation opportunity to bring transformative therapies to patients. Our call to action features a policy blueprint with recommendations to make this a reality.
Regenerative medicine includes gene therapies, cell therapies, and tissue-engineered products intended to augment, repair, replace, or regenerate organs, tissues, cells, genes, and metabolic processes in the body.
Regenerative medicine aims to alter the current practice of medicine by treating the root causes of disease and disorders.
ARM is the global voice of the cell and gene therapy sector, representing more than 400 members across 25 countries, including emerging and established biotechnology companies, academic and medical research institutions, and patient organizations.
As a community, ARM builds the future of medicine by convening the sector, facilitating influential exchanges on policies and practices, and advancing the narrative with data and analysis.